Replies to post #154 on Navidea Biopharmaceuticals Inc (NAVBQ)

[DewDiligence]

>> In this case he doesn't like this stock, I don't really care but for this stock he says the market has it right. <<

What the market finally got right is not the valuation per se, but rather the realization that the technically-open BLA doesn’t mean squat.

For all practical purposes, the RIGS BLA can be considered de novo; there is a new pivotal trial and (later) there will be a new CMC submission.

I like the stock a lot more now than I did at double the price before the FDA meeting.

[petprodoc]

I own stock to make money. Riding NEOP down from $1 plus to .43 just because it has good products/potential makes no sense.

I trade mainly, but not exclusively, by the charts and NEOP chart became a sell when the 50DMA was crossed. I like to chart trade companies I wouldn't mind holding long term. I used to be a buy & hold investor, but I happened on this group of short term traders who make these incredible trades. My own portfolio was up 175% in my first year of trading (the bb leaders do a lot better). Neop was mentioned on our bb at .44 cents and most got out at around $1. I think NEOP is going to be a hot one again. Quantix will make the company profitable. Riggs is a story the market makers can sell. My money is working elsewhere while I watch Neop for a reentry point.

Profiting in Bull and Bear Markets by Stan Weinstein is a great book that makes chart trading easy.

I am not a daytrader. I have held chart trades for as long as a year. I have seen your ID on Yahoo as we have traded GERN, IDEV, and GENR for good money.

I believe NEOP has good products and the potential to create a VTIV or ERES type chart.